Phio Pharmaceuticals Corp. (PHIO) Institutional Ownership

Ownership Summary

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is held by 17 institutional investors per 13F filings through December 2025.

• These investors collectively held 6.7% of Phio Pharmaceuticals's outstanding shares in December 2025, up from 3.5% in September 2025.
• Their total shares held in PHIO increased 92.44% from the prior quarter, while the number of investors in Phio Pharmaceuticals increased 41.67% year over year.
• Of these 17 funds, 12 grew their exposure to Phio Pharmaceuticals, 1 cut back, and 4 maintained positions.
• The aggregate institutional position in Phio Pharmaceuticals amounted to 363.85K shares as of December 2025, up by 174.78K shares quarter on quarter, and up 203.89K shares year over year.
• As of December 31, 2025, GEODE CAPITAL MANAGEMENT, LLC held the largest stake in Phio Pharmaceuticals with 92.64K shares, accounting for 1.69% of total shares outstanding.
• The biggest buyers of Phio Pharmaceuticals for the quarter ending December 2025 included GEODE CAPITAL MANAGEMENT, LLC (34.73K), Northern Trust Corp (23.76K), DRW Securities, LLC (22.64K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.09K), TWO SIGMA INVESTMENTS, LP (14.49K).
• Leading sellers of Phio Pharmaceuticals shares for the quarter ending December 2025 were Bank Of America Corp /De/ (1.39K).
• Phio Pharmaceuticals's 10 largest shareholders as of December 2025 include GEODE CAPITAL MANAGEMENT, LLC (92.64K), VANGUARD GROUP INC (87.63K), Cetera Investment Advisers (42.5K), Northern Trust Corp (23.76K), DRW Securities, LLC (22.64K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.09K), TWO SIGMA INVESTMENTS, LP (14.49K), StoneX Group Inc. (11.83K), Robertson Stephens Wealth Management, LLC (10.8K), Virtu Financial LLC (10.21K) per Business Quant data.